PDB Short entry for 2POY HEADER ISOMERASE/IMMUNOSUPPRESSANT 27-APR-07 2POY TITLE CRYPTOSPORIDIUM PARVUM CYCLOPHILIN TYPE PEPTIDYL-PROLYL CIS-TRANS TITLE 2 ISOMERASE CGD2_4120 IN COMPLEX WITH CYCLOSPORIN A COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEPTIDYL-PROLYL CIS-TRANS ISOMERASE; COMPND 3 CHAIN: A, B, C; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: CYCLOSPORIN A; COMPND 7 CHAIN: T, U, V; COMPND 8 SYNONYM: CICLOSPORIN, CICLOSPORINE; COMPND 9 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: CRYPTOSPORIDIUM PARVUM IOWA II; SOURCE 3 ORGANISM_TAXID: 353152; SOURCE 4 STRAIN: IOWA TYPE II; SOURCE 5 GENE: CGD2_4120; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: DH5A; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: P15_TEV/LIC; SOURCE 11 MOL_ID: 2; SOURCE 12 SYNTHETIC: YES; SOURCE 13 ORGANISM_SCIENTIFIC: TOLYPOCLADIUM INFLATUM; SOURCE 14 ORGANISM_TAXID: 29910 KEYWDS ISOMERASE-IMMUNOSUPPRESSANT COMPLEX, CYCLOPHILIN-CYCLOSPORIN COMPLEX, KEYWDS 2 CYCLOSPORIN A, IMMUNOSUPPRESSANT, CYCLOPHILIN, ISOMERASE, STRUCTURAL KEYWDS 3 GENOMICS, STRUCTURAL GENOMICS CONSORTIUM, SGC EXPDTA X-RAY DIFFRACTION AUTHOR A.K.WERNIMONT,J.LEW,T.HILLS,I.KOZIERADZKI,Y.H.LIN,A.HASSANALI,Y.ZHAO, AUTHOR 2 M.SCHAPIRA,C.H.ARROWSMITH,A.M.EDWARDS,J.WEIGELT,M.SUNDSTROM, AUTHOR 3 A.BOCHKAREV,R.HUI,J.D.ARTZ,T.XIAO,STRUCTURAL GENOMICS CONSORTIUM AUTHOR 4 (SGC) REVDAT 7 15-NOV-23 2POY 1 LINK REVDAT 6 30-AUG-23 2POY 1 LINK REVDAT 5 01-NOV-17 2POY 1 REMARK REVDAT 4 27-JUL-11 2POY 1 REMARK REVDAT 3 13-JUL-11 2POY 1 VERSN REVDAT 2 24-FEB-09 2POY 1 VERSN REVDAT 1 08-MAY-07 2POY 0 JRNL AUTH A.K.WERNIMONT,J.LEW,T.HILLS,I.KOZIERADZKI,Y.H.LIN, JRNL AUTH 2 A.HASSANALI,Y.ZHAO,M.SCHAPIRA,C.H.ARROWSMITH,A.M.EDWARDS, JRNL AUTH 3 J.WEIGELT,M.SUNDSTROM,A.BOCHKAREV,R.HUI,J.D.ARTZ,T.XIAO JRNL TITL CRYPTOSPORIDIUM PARVUM CYCLOPHILIN TYPE PEPTIDYL-PROLYL JRNL TITL 2 CIS-TRANS ISOMERASE CGD2_4120 IN COMPLEX WITH CYCLOSPORIN A. JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 34.88 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.3 REMARK 3 NUMBER OF REFLECTIONS : 51164 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.195 REMARK 3 R VALUE (WORKING SET) : 0.193 REMARK 3 FREE R VALUE : 0.233 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 2598 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.80 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.85 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2700 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 74.63 REMARK 3 BIN R VALUE (WORKING SET) : 0.2620 REMARK 3 BIN FREE R VALUE SET COUNT : 142 REMARK 3 BIN FREE R VALUE : 0.3400 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4096 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 315 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 21.33 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.25000 REMARK 3 B22 (A**2) : 0.43000 REMARK 3 B33 (A**2) : -0.18000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.135 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.130 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.090 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 2.868 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.948 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.925 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 4185 ; 0.015 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 5662 ; 1.536 ; 1.982 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 514 ; 6.452 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 163 ;33.327 ;24.417 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 636 ;13.486 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 13 ;11.433 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 623 ; 0.104 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3205 ; 0.006 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 2199 ; 0.222 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 2932 ; 0.319 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 319 ; 0.132 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 63 ; 0.180 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 18 ; 0.130 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2745 ; 0.916 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 4307 ; 1.472 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1616 ; 2.225 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1355 ; 3.360 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS REMARK 4 REMARK 4 2POY COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 02-MAY-07. REMARK 100 THE DEPOSITION ID IS D_1000042620. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 11-APR-07 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 3.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : CHESS REMARK 200 BEAMLINE : F1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.91770 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 51177 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.800 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.4 REMARK 200 DATA REDUNDANCY : 6.800 REMARK 200 R MERGE (I) : 0.10300 REMARK 200 R SYM (I) : 0.08300 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 6.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.86 REMARK 200 COMPLETENESS FOR SHELL (%) : 78.8 REMARK 200 DATA REDUNDANCY IN SHELL : 4.10 REMARK 200 R MERGE FOR SHELL (I) : 0.35300 REMARK 200 R SYM FOR SHELL (I) : 0.31200 REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 2PLU REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.81 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.15 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 25 % PEG 3350, 0.1 M CITRIC ACID PH REMARK 280 3.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 18.24100 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 63.93850 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 59.65150 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 63.93850 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 18.24100 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 59.65150 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1040 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 7820 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -7.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, T REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1000 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8100 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -7.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, U REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1010 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 7800 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -8.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, V REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. REMARK 400 HERE, CYCLOSPORIN A IS REPRESENTED BY THE SEQUENCE (SEQRES) REMARK 400 REMARK 400 THE CYCLOSPORIN A IS CYCLIC PEPTIDE, A MEMBER OF IMMUNOSUPPRESSANT REMARK 400 CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: CYCLOSPORIN A REMARK 400 CHAIN: T, U, V REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE. CYCLIZATION REMARK 400 IS ACHIEVED BY LINKING THE N- AND THE C- TERMINI. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 HIS A 2 REMARK 465 HIS A 3 REMARK 465 HIS A 4 REMARK 465 HIS A 5 REMARK 465 HIS A 6 REMARK 465 HIS A 7 REMARK 465 SER A 8 REMARK 465 SER A 9 REMARK 465 GLY A 10 REMARK 465 ARG A 11 REMARK 465 GLU A 12 REMARK 465 ASN A 13 REMARK 465 LEU A 14 REMARK 465 TYR A 15 REMARK 465 PHE A 16 REMARK 465 GLN A 17 REMARK 465 SER A 104 REMARK 465 MET B 1 REMARK 465 HIS B 2 REMARK 465 HIS B 3 REMARK 465 HIS B 4 REMARK 465 HIS B 5 REMARK 465 HIS B 6 REMARK 465 HIS B 7 REMARK 465 SER B 8 REMARK 465 SER B 9 REMARK 465 GLY B 10 REMARK 465 ARG B 11 REMARK 465 GLU B 12 REMARK 465 ASN B 13 REMARK 465 SER B 104 REMARK 465 MET C 1 REMARK 465 HIS C 2 REMARK 465 HIS C 3 REMARK 465 HIS C 4 REMARK 465 HIS C 5 REMARK 465 HIS C 6 REMARK 465 HIS C 7 REMARK 465 SER C 8 REMARK 465 SER C 9 REMARK 465 GLY C 10 REMARK 465 ARG C 11 REMARK 465 GLU C 12 REMARK 465 ASN C 13 REMARK 465 LEU C 14 REMARK 465 TYR C 15 REMARK 465 PHE C 16 REMARK 465 GLN C 17 REMARK 465 SER C 104 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG B 92 NE CZ NH1 NH2 REMARK 470 ARG C 107 CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 MVA T 4 C BMT T 5 N 0.312 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE A 83 -74.81 -140.19 REMARK 500 PHE A 152 -0.21 -140.35 REMARK 500 PHE B 83 -77.46 -149.37 REMARK 500 PHE C 83 -76.34 -141.29 REMARK 500 ARG C 92 5.03 -158.50 REMARK 500 ASP C 108 109.24 -56.33 REMARK 500 MLE T 10 -164.29 -105.06 REMARK 500 MLE U 10 -164.03 -112.81 REMARK 500 MLE V 2 71.07 -119.70 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN T OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN U OF CYCLOSPORIN A REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN V OF CYCLOSPORIN A REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BCK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 C REMARK 900 RELATED ID: 1C5F RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CYCLOPHILIN-LIKE DOMAIN FROM BRUGIA MALAYI REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CSA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF E.COLI CYCLOPHILIN (F112W) COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 1CWA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 1CWB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 1CWC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWF RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 D REMARK 900 RELATED ID: 1CWH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A MODIFIED AT POSITION 7 REMARK 900 RELATED ID: 1CWI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITION 7 REMARK 900 RELATED ID: 1CWJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN D AT POSITIONS 5 AND 7. REMARK 900 RELATED ID: 1CWL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 8 REMARK 900 RELATED ID: 1CWO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH NODIFIED REMARK 900 CYCLOSPORIN C AT POSITIONS 1, AND 9 REMARK 900 RELATED ID: 1CYA RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYB RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1CYN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN B COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 1 REMARK 900 RELATED ID: 1M63 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CALCINEURIN-CYCLOPHILIN-CYCLOSPORIN COMPLEX REMARK 900 RELATED ID: 1MF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CALCINEURIN COMPLEXED WITH HUMAN REMARK 900 CYCLOPHILIN AND CYCLOSPORIN A REMARK 900 RELATED ID: 1MIK RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 6 REMARK 900 RELATED ID: 1QNG RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN COMPLEXED REMARK 900 WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1QNH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN (DOUBLE REMARK 900 MUTANT) COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 1XQ7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TRYPANOSOMA CRUZI CYCLOPHILIN COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 2ESL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN C COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2OJU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN J COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2RMA RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN REMARK 900 A REMARK 900 RELATED ID: 2RMB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED REMARK 900 CYCLOSPORIN A AT POSITION 5 REMARK 900 RELATED ID: 2RMC RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE CYCLOPHILIN C COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 2WFJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PPIASE DOMAIN OF HUMAN CYCLOPHILIN G REMARK 900 COMPLEXED WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2X2C RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ACETYL-CYPA COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2X7K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PPIL1 COMPLEXED WITH CYCLOSPORINE A REMARK 900 RELATED ID: 2Z6W RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN D IN COMPLEX WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3BO7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOSPHILIN A FROM TOXOPLASMA GONDII REMARK 900 COMPLEXED WIT CYCLOSPORIN A REMARK 900 RELATED ID: 3CYS RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE HUMAN CYCLOSPORIN A COMPLEXED WITH REMARK 900 CYCLOSPORIN A REMARK 900 RELATED ID: 3EOV RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CYCLOPHILIN FROM LEISHMANIA DONOVANI COMPLEXED REMARK 900 WITH CYCLOSPORIN A REMARK 900 RELATED ID: 2PLU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CYCLOPHILIN TYPE REMARK 900 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE CGD2_4120, UNCOMPLEXED REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE N-TERMINAL 18 RESIDUES 'MHHHHHHSSGREDLYFNG' REMARK 999 IN CHAINS A, B AND C IS AN ENGINEERED EXPRESSION TAG DBREF 2POY A 1 18 PDB 2POY 2POY 1 18 DBREF 2POY A 19 186 UNP A3FQA7 A3FQA7_CRYPV 3 170 DBREF 2POY B 1 18 PDB 2POY 2POY 1 18 DBREF 2POY B 19 186 UNP A3FQA7 A3FQA7_CRYPV 3 170 DBREF 2POY C 1 18 PDB 2POY 2POY 1 18 DBREF 2POY C 19 186 UNP A3FQA7 A3FQA7_CRYPV 3 170 DBREF 2POY T 1 11 NOR NOR00033 NOR00033 1 11 DBREF 2POY U 1 11 NOR NOR00033 NOR00033 1 11 DBREF 2POY V 1 11 NOR NOR00033 NOR00033 1 11 SEQRES 1 A 186 MET HIS HIS HIS HIS HIS HIS SER SER GLY ARG GLU ASN SEQRES 2 A 186 LEU TYR PHE GLN GLY ASN PRO VAL VAL TYR PHE ASP ILE SEQRES 3 A 186 SER ILE GLY GLN THR PRO ALA GLY ARG ILE THR MET GLU SEQRES 4 A 186 LEU PHE ALA ASP LYS VAL PRO ILE THR ALA GLU ASN PHE SEQRES 5 A 186 ARG ALA LEU CYS THR GLY GLU LYS GLY MET GLY GLN SER SEQRES 6 A 186 GLY LYS PRO LEU CYS TYR THR GLY SER PHE PHE HIS ARG SEQRES 7 A 186 ILE ILE PRO GLN PHE MET ILE GLN GLY GLY ASP PHE THR SEQRES 8 A 186 ARG GLY ASP GLY THR GLY GLY GLU SER ILE TYR GLY SER SEQRES 9 A 186 LYS PHE ARG ASP GLU ASN PHE VAL TYR THR HIS ASP ALA SEQRES 10 A 186 PRO PHE LEU LEU SER MET ALA ASN ALA GLY PRO ASN THR SEQRES 11 A 186 ASN GLY SER GLN PHE PHE ILE THR THR VAL PRO CYS PRO SEQRES 12 A 186 TRP LEU ASP GLY LYS HIS VAL VAL PHE GLY LYS VAL LEU SEQRES 13 A 186 GLU GLY MET GLU VAL VAL LYS SER ILE GLU LYS CYS GLY SEQRES 14 A 186 SER GLN ASN GLY LYS PRO THR LYS SER VAL CYS ILE THR SEQRES 15 A 186 ALA SER GLY VAL SEQRES 1 B 186 MET HIS HIS HIS HIS HIS HIS SER SER GLY ARG GLU ASN SEQRES 2 B 186 LEU TYR PHE GLN GLY ASN PRO VAL VAL TYR PHE ASP ILE SEQRES 3 B 186 SER ILE GLY GLN THR PRO ALA GLY ARG ILE THR MET GLU SEQRES 4 B 186 LEU PHE ALA ASP LYS VAL PRO ILE THR ALA GLU ASN PHE SEQRES 5 B 186 ARG ALA LEU CYS THR GLY GLU LYS GLY MET GLY GLN SER SEQRES 6 B 186 GLY LYS PRO LEU CYS TYR THR GLY SER PHE PHE HIS ARG SEQRES 7 B 186 ILE ILE PRO GLN PHE MET ILE GLN GLY GLY ASP PHE THR SEQRES 8 B 186 ARG GLY ASP GLY THR GLY GLY GLU SER ILE TYR GLY SER SEQRES 9 B 186 LYS PHE ARG ASP GLU ASN PHE VAL TYR THR HIS ASP ALA SEQRES 10 B 186 PRO PHE LEU LEU SER MET ALA ASN ALA GLY PRO ASN THR SEQRES 11 B 186 ASN GLY SER GLN PHE PHE ILE THR THR VAL PRO CYS PRO SEQRES 12 B 186 TRP LEU ASP GLY LYS HIS VAL VAL PHE GLY LYS VAL LEU SEQRES 13 B 186 GLU GLY MET GLU VAL VAL LYS SER ILE GLU LYS CYS GLY SEQRES 14 B 186 SER GLN ASN GLY LYS PRO THR LYS SER VAL CYS ILE THR SEQRES 15 B 186 ALA SER GLY VAL SEQRES 1 C 186 MET HIS HIS HIS HIS HIS HIS SER SER GLY ARG GLU ASN SEQRES 2 C 186 LEU TYR PHE GLN GLY ASN PRO VAL VAL TYR PHE ASP ILE SEQRES 3 C 186 SER ILE GLY GLN THR PRO ALA GLY ARG ILE THR MET GLU SEQRES 4 C 186 LEU PHE ALA ASP LYS VAL PRO ILE THR ALA GLU ASN PHE SEQRES 5 C 186 ARG ALA LEU CYS THR GLY GLU LYS GLY MET GLY GLN SER SEQRES 6 C 186 GLY LYS PRO LEU CYS TYR THR GLY SER PHE PHE HIS ARG SEQRES 7 C 186 ILE ILE PRO GLN PHE MET ILE GLN GLY GLY ASP PHE THR SEQRES 8 C 186 ARG GLY ASP GLY THR GLY GLY GLU SER ILE TYR GLY SER SEQRES 9 C 186 LYS PHE ARG ASP GLU ASN PHE VAL TYR THR HIS ASP ALA SEQRES 10 C 186 PRO PHE LEU LEU SER MET ALA ASN ALA GLY PRO ASN THR SEQRES 11 C 186 ASN GLY SER GLN PHE PHE ILE THR THR VAL PRO CYS PRO SEQRES 12 C 186 TRP LEU ASP GLY LYS HIS VAL VAL PHE GLY LYS VAL LEU SEQRES 13 C 186 GLU GLY MET GLU VAL VAL LYS SER ILE GLU LYS CYS GLY SEQRES 14 C 186 SER GLN ASN GLY LYS PRO THR LYS SER VAL CYS ILE THR SEQRES 15 C 186 ALA SER GLY VAL SEQRES 1 T 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 U 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA SEQRES 1 V 11 DAL MLE MLE MVA BMT ABA SAR MLE VAL MLE ALA HET DAL T 1 5 HET MLE T 2 9 HET MLE T 3 9 HET MVA T 4 8 HET BMT T 5 13 HET ABA T 6 6 HET SAR T 7 5 HET MLE T 8 9 HET MLE T 10 9 HET DAL U 1 5 HET MLE U 2 9 HET MLE U 3 9 HET MVA U 4 8 HET BMT U 5 13 HET ABA U 6 6 HET SAR U 7 5 HET MLE U 8 9 HET MLE U 10 9 HET DAL V 1 5 HET MLE V 2 9 HET MLE V 3 9 HET MVA V 4 8 HET BMT V 5 13 HET ABA V 6 6 HET SAR V 7 5 HET MLE V 8 9 HET MLE V 10 9 HETNAM DAL D-ALANINE HETNAM MLE N-METHYLLEUCINE HETNAM MVA N-METHYLVALINE HETNAM BMT 4-METHYL-4-[(E)-2-BUTENYL]-4,N-METHYL-THREONINE HETNAM ABA ALPHA-AMINOBUTYRIC ACID HETNAM SAR SARCOSINE FORMUL 4 DAL 3(C3 H7 N O2) FORMUL 4 MLE 12(C7 H15 N O2) FORMUL 4 MVA 3(C6 H13 N O2) FORMUL 4 BMT 3(C10 H19 N O3) FORMUL 4 ABA 3(C4 H9 N O2) FORMUL 4 SAR 3(C3 H7 N O2) FORMUL 7 HOH *315(H2 O) HELIX 1 1 VAL A 45 GLY A 58 1 14 HELIX 2 2 CYS A 142 ASP A 146 5 5 HELIX 3 3 GLY A 158 CYS A 168 1 11 HELIX 4 4 VAL B 45 GLY B 58 1 14 HELIX 5 5 CYS B 142 ASP B 146 5 5 HELIX 6 6 GLY B 158 LYS B 167 1 10 HELIX 7 7 VAL C 45 GLY C 58 1 14 HELIX 8 8 CYS C 142 ASP C 146 5 5 HELIX 9 9 GLY C 158 LYS C 167 1 10 SHEET 1 AA 8 ARG A 78 ILE A 80 0 SHEET 2 AA 8 MET A 84 GLY A 87 -1 O MET A 84 N ILE A 80 SHEET 3 AA 8 PHE A 135 THR A 138 -1 O PHE A 135 N GLY A 87 SHEET 4 AA 8 LEU A 120 MET A 123 -1 O LEU A 120 N THR A 138 SHEET 5 AA 8 VAL A 151 GLU A 157 -1 N PHE A 152 O LEU A 121 SHEET 6 AA 8 THR A 31 LEU A 40 -1 O THR A 37 N LEU A 156 SHEET 7 AA 8 VAL A 21 ILE A 28 -1 O VAL A 22 N MET A 38 SHEET 8 AA 8 VAL A 179 GLY A 185 -1 O CYS A 180 N SER A 27 SHEET 1 BA 2 TYR B 15 PHE B 16 0 SHEET 2 BA 2 ASN B 19 ILE B 28 -1 O ASN B 19 N PHE B 16 SHEET 1 BB 8 ARG B 78 ILE B 80 0 SHEET 2 BB 8 MET B 84 GLY B 87 -1 O MET B 84 N ILE B 80 SHEET 3 BB 8 PHE B 135 THR B 138 -1 O PHE B 135 N GLY B 87 SHEET 4 BB 8 LEU B 120 MET B 123 -1 O LEU B 120 N THR B 138 SHEET 5 BB 8 VAL B 151 GLU B 157 -1 N PHE B 152 O LEU B 121 SHEET 6 BB 8 THR B 31 LEU B 40 -1 O THR B 37 N LEU B 156 SHEET 7 BB 8 ASN B 19 ILE B 28 -1 O PRO B 20 N LEU B 40 SHEET 8 BB 8 VAL B 179 GLY B 185 -1 O CYS B 180 N SER B 27 SHEET 1 BC 8 ARG B 78 ILE B 80 0 SHEET 2 BC 8 MET B 84 GLY B 87 -1 O MET B 84 N ILE B 80 SHEET 3 BC 8 PHE B 135 THR B 138 -1 O PHE B 135 N GLY B 87 SHEET 4 BC 8 LEU B 120 MET B 123 -1 O LEU B 120 N THR B 138 SHEET 5 BC 8 VAL B 151 GLU B 157 -1 N PHE B 152 O LEU B 121 SHEET 6 BC 8 THR B 31 LEU B 40 -1 O THR B 37 N LEU B 156 SHEET 7 BC 8 ASN B 19 ILE B 28 -1 O PRO B 20 N LEU B 40 SHEET 8 BC 8 TYR B 15 PHE B 16 -1 O PHE B 16 N ASN B 19 SHEET 1 BD 2 VAL B 179 GLY B 185 0 SHEET 2 BD 2 ASN B 19 ILE B 28 -1 O TYR B 23 N GLY B 185 SHEET 1 CA 8 ARG C 78 ILE C 80 0 SHEET 2 CA 8 MET C 84 GLY C 87 -1 O MET C 84 N ILE C 80 SHEET 3 CA 8 PHE C 135 THR C 138 -1 O PHE C 135 N GLY C 87 SHEET 4 CA 8 LEU C 120 MET C 123 -1 O LEU C 120 N THR C 138 SHEET 5 CA 8 VAL C 151 GLU C 157 -1 N PHE C 152 O LEU C 121 SHEET 6 CA 8 THR C 31 LEU C 40 -1 O THR C 37 N LEU C 156 SHEET 7 CA 8 VAL C 21 ILE C 28 -1 O VAL C 22 N MET C 38 SHEET 8 CA 8 VAL C 179 GLY C 185 -1 O CYS C 180 N SER C 27 LINK C DAL T 1 N MLE T 2 1555 1555 1.34 LINK N DAL T 1 C ALA T 11 1555 1555 1.32 LINK C MLE T 2 N MLE T 3 1555 1555 1.33 LINK C MLE T 3 N MVA T 4 1555 1555 1.34 LINK C MVA T 4 N BMT T 5 1555 1555 1.65 LINK C BMT T 5 N ABA T 6 1555 1555 1.33 LINK C ABA T 6 N SAR T 7 1555 1555 1.33 LINK C SAR T 7 N MLE T 8 1555 1555 1.33 LINK C MLE T 8 N VAL T 9 1555 1555 1.33 LINK C VAL T 9 N MLE T 10 1555 1555 1.33 LINK C MLE T 10 N ALA T 11 1555 1555 1.33 LINK C DAL U 1 N MLE U 2 1555 1555 1.35 LINK N DAL U 1 C ALA U 11 1555 1555 1.34 LINK C MLE U 2 N MLE U 3 1555 1555 1.34 LINK C MLE U 3 N MVA U 4 1555 1555 1.35 LINK C MVA U 4 N BMT U 5 1555 1555 1.77 LINK C BMT U 5 N ABA U 6 1555 1555 1.33 LINK C ABA U 6 N SAR U 7 1555 1555 1.34 LINK C SAR U 7 N MLE U 8 1555 1555 1.34 LINK C MLE U 8 N VAL U 9 1555 1555 1.33 LINK C VAL U 9 N MLE U 10 1555 1555 1.34 LINK C MLE U 10 N ALA U 11 1555 1555 1.35 LINK C DAL V 1 N MLE V 2 1555 1555 1.33 LINK N DAL V 1 C ALA V 11 1555 1555 1.33 LINK C MLE V 2 N MLE V 3 1555 1555 1.33 LINK C MLE V 3 N MVA V 4 1555 1555 1.34 LINK C BMT V 5 N ABA V 6 1555 1555 1.33 LINK C ABA V 6 N SAR V 7 1555 1555 1.34 LINK C SAR V 7 N MLE V 8 1555 1555 1.33 LINK C MLE V 8 N VAL V 9 1555 1555 1.33 LINK C VAL V 9 N MLE V 10 1555 1555 1.34 LINK C MLE V 10 N ALA V 11 1555 1555 1.33 SITE 1 AC1 19 ARG A 78 PHE A 83 GLN A 86 GLY A 95 SITE 2 AC1 19 ALA A 124 ASN A 125 ALA A 126 GLN A 134 SITE 3 AC1 19 PHE A 136 TRP A 144 HIS A 149 GLN B 30 SITE 4 AC1 19 LYS C 167 CYS C 168 THR C 176 HOH T2001 SITE 5 AC1 19 HOH T2002 HOH T2003 HOH T2004 SITE 1 AC2 26 TYR B 15 PHE B 16 VAL B 21 ARG B 78 SITE 2 AC2 26 PHE B 83 GLN B 86 GLY B 95 ALA B 124 SITE 3 AC2 26 ASN B 125 ALA B 126 GLN B 134 PHE B 136 SITE 4 AC2 26 TRP B 144 LEU B 145 HIS B 149 GLU B 157 SITE 5 AC2 26 VAL B 186 HOH B2017 HOH B2036 HOH B2039 SITE 6 AC2 26 HOH B2077 HOH U2001 HOH U2002 MLE V 3 SITE 7 AC2 26 MLE V 10 ALA V 11 SITE 1 AC3 20 TRP B 144 GLU B 160 ARG C 78 PHE C 83 SITE 2 AC3 20 GLN C 86 GLY C 95 ALA C 124 ASN C 125 SITE 3 AC3 20 ALA C 126 GLN C 134 PHE C 136 TRP C 144 SITE 4 AC3 20 LEU C 145 HIS C 149 DAL U 1 MLE U 2 SITE 5 AC3 20 ALA U 11 HOH V2001 HOH V2002 HOH V2003 CRYST1 36.482 119.303 127.877 90.00 90.00 90.00 P 21 21 21 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.027411 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008382 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007820 0.00000